Andrea Ghelli

People, Researcher



Acute lymphoblastic leukemia (ALL) is an onco-hematological disease affecting lymphoid hematopoietic precursors. Despite the great achievements in the treatment of ALL patients, the prognosis for different sub-groups of ALL is still poor. Currently, the therapeutic strategies use different chemotherapy regimens in combination with target therapeutics against leukemia-specific genomic alterations. Using these approaches, a great percentage of ALL patients (80-90%) reach the complete remission of the disease. Unlikely, around 30-40% of ALL patients, after an initial response to the therapy, became refractory or relapsed.

Dr. Andrea Ghelli studies the molecular and functional mechanisms underlying the development of chemo-resistance in ALL patients and, in particular, his research is focused on the understanding of the mechanism that leukemia cells trigger in order to respond to DNA damages. The goal of these studies is to identify novel potential therapeutic targets that can increase the efficacy of conventional antineoplastic agents and to improve, consequently, the therapeutic options for adult patients affected by ALL.

Dr. Andrea Ghelli graduated in Medical Biotechnology at the University of Bologna (2012) and, at the same university, obtained a PhD in Biomedical Sciences (2016). During this period, he demonstrated that ALL cells are characterized by altered functionality of different genes involved in DNA damage response (DDR) pathways in comparison with healthy hematopoietic cells. Dr. Andrea Ghelli continued the study of DNA damage repair mechanisms in acute leukemia first as a research fellow at the Department of Specialized, Diagnostic and Experimental Medicine (DIMES) of Bologna (2016-2019) and, subsequently, as a senior researcher at the IRCCS-Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” (2019-2021).